A Phase 4 interventional study of Carotid Ultrasound and High-intensity lipid-lowering therapy in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Systemic Lupus Erythematosus (SLE), sponsored by Instituto de Investigación Marqués de Valdecilla. Recruiting at 17 sites in Spain. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Instituto de Investigación Marqués de Valdecilla · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Arthritis, Rheumatoid with a site in Spain — 20 open to participants now, 35 under way, 3 of them phase 3. Arthritis, Rheumatoid · Spain.
Among the 265 studies in Arthritis, Rheumatoid with a site in Spain, this one is the 28th largest by planned enrollment of the 220 interventional ones that give a count, is one of 6 that started in 2026, is one of 22 in phase 4, reaches primary completion later than 32 of the 34 other live ones, and was the 262nd registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →20 of the 265 studies in Arthritis, Rheumatoid with a site in Spain are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Spain, United States, Belgium and 8 more countries
Ages 18–65
Hoffmann-La Roche · Sites in Spain, United States, Argentina and 2 more countries
Ages 18+
Quell Therapeutics Limited · Sites in Spain, Germany, United Kingdom
Ages 18+
GlaxoSmithKline · Sites in Spain, Argentina, Brazil and 6 more countries
Ages 18–70
AstraZeneca · Sites in Spain, United States, Australia and 3 more countries
Ages 18–75
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 88 · Phase 3 88 · Phase 4 22
First in 2000; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,117 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 299 across the 220 interventional studies, 210 across the 45 observational. Of the 219 that completed or were terminated, 161 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
243 of 265 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigación Marqués de Valdecilla is the lead sponsor of 34 studies on the registry; 12 are open to participants now.
Instituto de Investigación Marqués de Valdecilla has 2 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
9 of the studies in Arthritis, Rheumatoid with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT05062421Fundación Pública Andaluza para la gestión de la Investigación en SevillaPersistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis. | 2026-12-01 |
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
Add all 9 to your calendar (.ics) → With an account.
Among the 265 studies in Arthritis, Rheumatoid with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PREVENER is a randomized, open-label, multicenter, phase IV clinical trial designed to evaluate the efficacy and safety of a carotid ultrasound-based strategy for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases (IRD).
Patients with IRD, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), and systemic lupus erythematosus (SLE), have a 50% higher risk of cardiovascular (CV) events compared to the general population. However, conventional CV risk scores (SCORE2/OP) systematically underestimate this risk, leaving many high-risk patients without appropriate preventive treatment.
Patients aged ≥50 years with IRD and low-to-moderate CV risk according to SCORE2/OP will be randomized 1:1 to either an experimental group (carotid ultrasound to detect subclinical atherosclerosis) or a control group (standard care according to ESC 2021 guidelines). Patients in the experimental group with carotid plaques will be reclassified as very high CV risk and treated with high-intensity statins (LDL target \<55 mg/dL). The primary endpoint is the incidence of major adverse cardiovascular events (MACE) over 48 months of follow-up.
Background:
Patients with chronic inflammatory rheumatic diseases (RA, PsA, AxSpA, SLE) carry a significantly increased risk of atherosclerotic cardiovascular events compared to the general population. This excess risk is largely attributed to the pro-atherogenic effect of chronic inflammation. Despite this, conventional CV risk stratification tools such as SCORE2/OP do not account for inflammation-related risk, leading to systematic underestimation of CV risk in these patients. Data from the CARMA project demonstrated that 53% of CV events in Spanish patients with IRD occurred in those classified as low-to-moderate risk by SCORE2/OP, highlighting the urgent need for improved risk stratification strategies.
Carotid ultrasound for the detection of subclinical atherosclerosis (carotid plaques) has been proposed as a modifier of CV risk in the ESC 2021 guidelines. The presence of carotid plaques automatically reclassifies individuals to very high CV risk, warranting intensive lipid-lowering therapy. However, no randomized clinical trial has evaluated the efficacy of this strategy in patients with IRD.
Study Design:
PREVENER is an open-label, randomized, multicenter, phase IV clinical trial. Patients aged ≥50 years with IRD (RA by ACR/EULAR 2010 criteria, PsA by CASPAR criteria, AxSpA by ASAS criteria, or SLE by ACR/EULAR 2019 criteria) and low-to-moderate CV risk according to SCORE2/OP will be enrolled across 17 Spanish hospitals.
Eligible patients will be randomized 1:1 to:
Randomization will be performed using REDCap, stratified by age, sex, classic CV risk factors, lipid-lowering treatment, rheumatic disease, and advanced therapy use.
Primary Endpoint:
Incidence of major adverse cardiovascular events (MACE), defined as: acute myocardial infarction or stroke, hospitalization for unstable angina, arterial revascularization for peripheral arterial disease, or CV death.
Secondary Endpoints:
Follow-up:
All patients will be followed for 48 months. Patients on lipid-lowering treatment will have monthly visits during the intensification phase (maximum 5 visits) until therapeutic target is achieved, followed by semi-annual visits until month 48. Patients not requiring lipid-lowering treatment will have semi-annual visits throughout.
Statistical Analysis:
The primary analysis will follow an intention-to-treat approach. Cox regression models will be used to calculate Hazard Ratios with 95% confidence intervals, adjusted for relevant covariates. Kaplan-Meier survival curves will be compared using the log-rank test. Based on a 4-year incidence of first CV event of 3.2% in patients aged ≥50 years with IRD and low-to-moderate SCORE2/OP risk (CARMA project), and assuming a 50% reduction in events among experimental-group patients with carotid plaques (estimated to account for 85% of events in that group), the expected incidence in the experimental group is 1.91%. With 80% power and a two-sided alpha of 0.05, 1,064 patients are required (1,117 allowing for \<5% loss to follow-up). An interim analysis will be performed at 50% of expected events using the O'Brien-Fleming stopping rule, reviewed by an independent Data Safety Monitoring Board (DSMB).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Fulfillment of classification criteria for at least one of the following inflammatory rheumatic diseases:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo carotid ultrasound within 30 days of randomization. Patients with carotid plaques are reclassified as very high cardiovascular risk and initiated on high-intensity statin therapy (LDL target \< 55 mg/dL). Patients without carotid plaques are managed according to ESC 2021 guidelines.
Diagnostic Test: Carotid Ultrasound · Drug: High-intensity lipid-lowering therapy
Patients are managed according to standard ESC 2021 cardiovascular prevention guidelines throughout the study, without carotid ultrasound assessment.
Other: Standard care according to ESC 2021 guidelines
Carotid ultrasound performed to detect subclinical atherosclerosis (carotid plaques) according to Mannheim consensus criteria. The presence of carotid plaques triggers reclassification to very high cardiovascular risk and initiation of high-intensity lipid-lowering therapy.
Sequential lipid-lowering therapy initiated in experimental group patients with carotid plaques, targeting LDL \< 55 mg/dL. Treatment includes high-intensity statins (atorvastatin 40-80mg, rosuvastatin 20-40mg), with possible addition of ezetimibe, bempedoic acid, and/or PCSK9 inhibitors if target is not achieved.
Lipid-lowering treatment indicated and managed according to ESC 2021 cardiovascular prevention guidelines, based on SCORE2/OP risk stratification, without carotid ultrasound assessment.
Incidence of Major Adverse Cardiovascular Events (MACE)
Composite of acute myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization for peripheral arterial disease, or cardiovascular death, whichever occurs first.
Time frame: 48 months
Number of Participants Experiencing an Acute Myocardial Infarction or Stroke
Incidence of acute myocardial infarction or stroke during the follow-up period.
Time frame: 48 months
Number of Participants Hospitalized for Unstable Angina
Incidence of hospital admissions due to unstable angina during the follow-up period.
Time frame: 48 months
Number of Participants Requiring Arterial Revascularization for Peripheral Arterial Disease
Incidence of arterial revascularization procedures required for peripheral arterial disease during the follow-up period.
Time frame: 48 months
Number of Participants Experiencing Cardiovascular Death
Incidence of cardiovascular death during the follow-up period.
Time frame: 48 months
Number of Participants Experiencing a Major Cardiovascular Event. Stratified by Rheumatic Disease Subgroup
Evaluation of the incidence of major cardiovascular events (acute myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization for peripheral artery disease, or cardiovascular death) analyzed individually for each included inflammatory disease (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and systemic lupus erythematosus).
Time frame: 48 months
Number of Participants Experiencing a Major Cardiovascular Event. Analyzed by Sex
This measure evaluates the efficacy of the strategy by comparing the incidence of individual cardiovascular events (acute myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization or cardiovascular death) between male and female participants.
Time frame: 48 months
Incidence of adverse events
Time frame: 48 months
LDL cholesterol levels
Time frame: 48 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Apr 2031, 60 months after the start.
Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 60 months is above that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigación Marqués de Valdecilla